IX Biopharma Responses.pdf

iX Biopharma Ltd. responds to Securities Investors Association (Singapore) questions:
1. Results are "exceptional" due to 193% revenue increase to $5.91 million, driven by medicinal cannabis revenue growth and improved gross operating profit.
2. The company manages expenses by maintaining a disciplined approach to cost control, with sales and marketing expenses increasing 53% despite 193% revenue growth.
3. The board guides management to work towards profitability and cash flow generation by growing sales and monetizing pharmaceutical assets.
4. The current facility can accommodate more growth, with plans to expand capacity as it approaches full utilization, requiring new capital expenditure.
5. Revenue from medicinal cannabis in Australia is recognized over time as it is accounted for as a rendering of service.
6. MeltMed's US market entry strategy is outlined in the Annual Report, with a competitive advantage in the highly fragmented US market.
7. The outcome of China Resources Pharmaceutical Group's registration dossier submission will be announced once informed.
8. The board elaborates on the rationale and selection criteria for appointing Mr. Teo Woon Keng John as an independent director, with his background and expertise contributing to the board's effectiveness.